Last reviewed · How we verify
NCT07266584: PRIMAlia
Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration
NA trial testing PRIMA Products in Stargardt Disease in 5 participants. Currently enrolling.
1 March 2029
Quick facts
| Lead sponsor | Science Corporation |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 12 March 2026 |
| Primary completion | 1 March 2029 |
| Estimated completion | 1 March 2031 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- PRIMA Products
Conditions studied
- Stargardt Disease — all drugs for Stargardt Disease →
- Retinitis Pigmentosa (RP) — all drugs for Retinitis Pigmentosa (RP) →
- Inherited Retinal Degeneration — all drugs for Inherited Retinal Degeneration →
Sponsor
Science Corporation — full company profile →
Who can join
18 and older, any sex, with Stargardt Disease or Retinitis Pigmentosa (RP). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis Pigmentosa). Eligible participants will be implanted with the PRIMA Stim implant. The participants will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA Products. The purpose of this study is to gather enough clinical data to support the clinical evaluation required for the continuous development to improve the PRIMA Products.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07266584
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stargardt Disease
Currently open trials in the same condition.
- NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting
- NCT07439887 — Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients · Phase 1, PHASE2 · recruiting
- NCT07417566 — A Study of DC6001 Tablet in Healthy Chinese Adult Subjects · Phase 1 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06942572 — A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficac · Phase 1, PHASE2 · recruiting
Other Science Corporation trials
Trials by the same sponsor.
- NCT03333954 — Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degenerat · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07266584 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Science Corporation
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07266584.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing